openPR Logo
Press release

Global Movement Disorder Market Expected to Secure Notable Revenue Share during 2017-2026|| Global key players- Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, Mayo Clinic

01-23-2019 08:30 AM CET | Health & Medicine

Press release from: Fact.MR

Global Movement Disorder Market Expected to Secure Notable

Prevalence of the mental disorders has continued to remain high among the old aged population globally. Neurological diseases such as Huntington’s disease, Parkinson’s disease and multiple symptom atrophy (MSA) continues to propel demand for management of the movement disorders. Lack of production of brain chemical dopamine by the nerve cells in the brain leads to uncoordinated movements and mental disorders that impact the everyday activities of the persons. According to FactMR, the global Movement Disorder Market is expected to represent a value of over US$ 1,000 Mn by the end of 2026.

Request Sample Copy is Available at: https://www.factmr.com/connectus/sample?flag=S&rep_id=329

Inability to generate movements affects the functioning of nerves, brain and the spinal cord adversely. Neurological disorders has led to surge in diseases such as trauma, convulsive diseases, cerebrovascular diseases, brain tumors and degenerative diseases. Growing prevalence of such mental disorders impact the cognitive abilities and lead to increasing prevalence of insomnia, depression, swallowing, inability to chew and speaking. Surge in awareness attributed to increasing prevalence of the neurological diseases is expected to impact growth of the global movement disorders market positively.

FDA Approval to Boost Sales of Medications

Medications and treatments approved by FDA is also expected to impact growth of the global movement disorder market. Xadago (safinamide) tablets and Ingrezza capsules are two drugs that have recently cleared the FDA pipeline. Ingrezza capsules have recently received approval for treatment of dyskinesia and Xadago (safinamide) tablets have received approval of Parkinson’s disease. In addition, the FDA has also approved implantation of brain to reduce the tremor symptoms. These factors are further expected to boost growth of the global movement disorders market.

Advanced Features to Impact Growth of the Global Market

In order to gain a competitive edge, various companies operating in the global movement disorder market are focusing on product innovation and developments. Manufacturers are mainly concentrating on incorporating advanced technology in the medical devices for faster recovery and improved results. Equipped with the advanced features such as sensors, 360-degree stabilizing solutions and cloud technology. Parkinson’s spoon equipped with advanced technological features enable the end users to retrieve and store information regarding the status of the unwanted tremors and generates the algorithm of tremor patterns for optimal stabilization. Moreover, the manufacturers operating in the global market are offering the electronic stabilizing handle, which comprises everyday spoon, spork, soup spoon and a fork. Bound to these factors, the global movement disorders market is expected to witness significant growth during the forecast period.

Browse Complete Report Summary: https://www.factmr.com/report/329/movement-disorder-market

On the other hand, various factors continue to impact growth of the global movement disorders market negatively. Lack of investment in research and development will continue to inhibit growth of the global movement disorder market. In addition, slow approval of the medications developed is further likely to impact growth of the global market negatively. Moreover, poor method of therapeutics conducted continues to pose significant challenges towards growth of the global market.

Parkinson’s disease to Represent a Leading Segment

Growing need for medical devices with the uninterrupted functioning for treatment of the neurological disorders has led to an upsurge in adoption of rechargeable deep brain stimulator devices. On the basis of product type, the rechargeable deep brain stimulator devices segment is expected to generate significant revenues, accounting for a value of over US$ 500 Mn by the end of 2026. However, the non-rechargeable deep brain stimulator devices product type segment is expected to register the highest CAGR during the forecast period.

Based on end user, the hospitals segment is expected to represent the highest revenue growth, recording a value of less than US$ 100 Mn by the end of 2017. On the other hand, the clinics end user segment is expected to register a robust through 2026.

By application, the Parkinson’s disease segment is expected to represent a significant revenue growth, accounting for a value of over US$ 400 Mn by the end of 2026. In contrary to this, the dystonia application segment is expected to register a healthy CAGR throughout the forecast period.

Competition Tracking

Leading market players operating in the global movement disorder market include Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation and Mayo Clinic.

Make an inquiry for purchasing this report: https://www.factmr.com/checkout/329/S

About FactMR
FactMR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market insights reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; that's why we publish multi-industry global, regional, and country-specific research reports.

Contact Us
Fact.MR
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Email: sales@factmr.com
Web: https://www.factmr.com/
Blog: https://factmrblog.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Movement Disorder Market Expected to Secure Notable Revenue Share during 2017-2026|| Global key players- Medtronic Plc, Abbott Laboratories, Boston Scientific Corporation, Mayo Clinic here

News-ID: 1524176 • Views:

More Releases from Fact.MR

Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2034
04-24-2024 | Health & Medicine
Fact.MR
Hemoglobinopathy Market Forecast Growing at 8.3% CAGR to Reach $1.7 Billion by 2 …
In 2024, the global hemoglobinopathy market (ヘモグロビン症市場) is estimated to be worth US$788.1 million, with a projected compound annual growth rate (CAGR) of 8.3% through 2034. By 2034, the market size is expected to exceed US$1,745.7 million. The rise of genetic testing has led to a significant shift in the hemoglobinopathy market towards personalized medication. Companies are leveraging this trend to develop tailored treatment plans based on each patient's DNA
Sales Forecast of Elder Care Product Market to Reach US$ 56.7 Billion by 2034 with a 6.7% CAGR
04-24-2024 | Health & Medicine
Fact.MR
Sales Forecast of Elder Care Product Market to Reach US$ 56.7 Billion by 2034 wi …
The global elder care product market (高齢者介護製品市場) is anticipated to reach a value of US$ 29,600.2 million by 2024 and is expected to exceed US$ 56,719.4 million by 2034. Sales of these products are forecasted to grow at a CAGR of 6.7% through 2034, driven by the growing trend of aging-in-place. This trend is fueling innovations in technology integration, wearable health devices, and personalized safety solutions. Increasing awareness about elder
Veterinary Oncology Market Predicts 12% CAGR Through 2033 With a US$ 800 Million
04-24-2024 | Health & Medicine
Fact.MR
Veterinary Oncology Market Predicts 12% CAGR Through 2033 With a US$ 800 Million
In 2023, the veterinary oncology market (獣医腫瘍学市場) was valued at US$ 260 million, and it's anticipated to reach US$ 800 million by the end of 2033, with a projected compound annual growth rate (CAGR) of 12% from 2023 to 2033. Veterinary oncology focuses on caring for pets diagnosed with cancer, with the goal of enhancing their overall quality of life. Cancer is the leading cause of mortality among companion animals,
Sales of Luxury Eyewear are forecasted to reach US$ 56 billion by 2033
Sales of Luxury Eyewear are forecasted to reach US$ 56 billion by 2033
According to Fact.MR, a trusted provider of market research and competitive intelligence, the global Luxury Eyewear Market was valued at US$ 40 billion in 2023. Projections suggest that by the conclusion of 2033, this market is anticipated to escalate to US$ 56 billion. Forecasts indicate a steady Compound Annual Growth Rate (CAGR) of 3.4% in the global demand for luxury eyewear from 2023 to 2033. The surge in luxury eyewear sales

All 5 Releases


More Releases for Parkinson’s

Parkinson’s Disease Therapeutics Market 2021 | Detailed Report
Global Parkinson’s Disease Therapeutics Market 2021-2027, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market. An exclusive data offered in this report is collected by research and industry experts team. Get Free Sample PDF (including full TOC, Tables and
Parkinson’s Disease Treatment Market 2021 | Detailed Report
Parkinson’s Disease Treatment Market Forecasts report provided to identify significant trends, drivers, influence factors in global and regions, agreements, new product launches and acquisitions, Analysis, market drivers, opportunities and challenges, risks in the market, cost and forecasts to 2027. Get Free Sample PDF (including full TOC, Tables and Figures) of Parkinsons Disease Treatment Market @ https://www.reportsnreports.com/contacts/requestsample.aspx?name=5024082 The report provides a comprehensive analysis of company profiles listed below: - Teva - Roche - Prothena - Acorda
Parkinson’s disease Therapeutics Parkinson’s disease Therapeutics Market to …
This report studies the global Parkinson's Disease Therapeutics market, analyzes and researches the Parkinson's Disease Therapeutics development status and forecast in United States, EU, Japan, China, India and Southeast Asia. This report focuses on the top players in global market, like GSK Novartis Boehringer Ingelheim Teva Pharmaceutical Abbvie ….. Ask for sample copy @ https://www.researchtrades.com/request-sample/1199125 Market segment by Regions/Countries, this report covers United States EU Japan China India Southeast Asia Market segment by Type, Parkinson's Disease Therapeutics can be split into Medications Therapeutics Medical Devices Therapeutics Buy
US Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in the United States in recent years and it most likely to continue rising in the near future. It has been estimated that at least 500,000 people in the United States currently have been diagnosed with this disease. The society pays a significant amount towards treating this disease in the country. It is estimated that the total cost to the nation exceeds
Europe Parkinson’s Disease Drug Pipeline Analysis
Parkinson’s disease incidence has been on a rise in Europe in recent years and it most likely to continue rising in the near future. It has been estimated that currently, more than 1 million in Europe are affected by Parkinson’s disease. This figure is most likely to double by 2030. Among the most common neurodegenerative disease (after Alzheimer’s disease), Parkinson’s is the second most common and it is expected that
Parkinson’s Disease - Heat Map and Analysis
ReportsWorldwide has announced the addition of a new report title Parkinson’s Disease - Heat Map and Analysis to its growing collection of premium market research reports. Parkinson’s disease (PD) is a chronic and progressive neurodegenerative disorder characterized by the progressive loss of muscular control, leading to resting tremor, rigidity, akinesia and postural reflex impairment. PD is an age-related disorder; symptoms typically begin to first appear in patients in their mid-sixties,